- Home
- UBCP vs ALXO Comparison
UBCP vs ALXO Comparison
Compare UBCP & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBCP
- ALXO
- Stock Information
- Founded
- UBCP 1902
- ALXO 2015
- Country
- UBCP United States
- ALXO United States
- Employees
- UBCP N/A
- ALXO N/A
- Industry
- UBCP Major Banks
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- UBCP Finance
- ALXO Health Care
- Exchange
- UBCP Nasdaq
- ALXO Nasdaq
- Market Cap
- UBCP 77.3M
- ALXO 76.5M
- IPO Year
- UBCP N/A
- ALXO 2020
- Fundamental
- Price
- UBCP $12.70
- ALXO $1.74
- Analyst Decision
- UBCP
- ALXO Buy
- Analyst Count
- UBCP 0
- ALXO 6
- Target Price
- UBCP N/A
- ALXO $11.00
- AVG Volume (30 Days)
- UBCP 6.1K
- ALXO 1.1M
- Earning Date
- UBCP 02-04-2025
- ALXO 03-06-2025
- Dividend Yield
- UBCP 4.20%
- ALXO N/A
- EPS Growth
- UBCP N/A
- ALXO N/A
- EPS
- UBCP 1.37
- ALXO N/A
- Revenue
- UBCP $29,231,000.00
- ALXO N/A
- Revenue This Year
- UBCP N/A
- ALXO N/A
- Revenue Next Year
- UBCP $7.23
- ALXO N/A
- P/E Ratio
- UBCP $9.30
- ALXO N/A
- Revenue Growth
- UBCP N/A
- ALXO N/A
- 52 Week Low
- UBCP $11.40
- ALXO $1.19
- 52 Week High
- UBCP $15.50
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- UBCP 45.27
- ALXO 53.13
- Support Level
- UBCP $12.33
- ALXO $1.56
- Resistance Level
- UBCP $12.96
- ALXO $1.94
- Average True Range (ATR)
- UBCP 0.63
- ALXO 0.16
- MACD
- UBCP -0.06
- ALXO -0.01
- Stochastic Oscillator
- UBCP 21.89
- ALXO 50.00
About UBCP United Bancorp Inc.
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. The company's primary deposit products are checking, savings and term certificate accounts and its primary lending products are residential mortgages, commercial and installment loans. The company serves customers mainly located in Athens, Belmont, Carroll, Fairfield, Harrison, Jefferson and Tuscarawas Counties in Ohio and Marshall and Ohio Counties in West Virginia and the surrounding localities in northeastern, east-central and southeastern Ohio and include a wide range of individuals, businesses and other organizations.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.